Independent reference. Not affiliated with, endorsed by, or speaking for the U.S. Food and Drug Administration.
FDA Medication Tracker

← All approvals · Eye · 2026

Lumvoa (veligrotug-vvze)

The FDA approved Lumvoa (veligrotug-vvze) on June 26, 2026 to treat thyroid eye disease.
Brand name
Lumvoa
Generic name
veligrotug-vvze
FDA approval date
June 26, 2026
Approved use (FDA wording)
To treat thyroid eye disease
Company
Viridian Therapeutics Inc.
Application
BLA761530
Dosage form / route
INJECTION
Boxed warning on label
Not listed
Category on this site
Eye

Indications and usage, from the FDA label

LUMVOA is indicated for the treatment of thyroid eye disease regardless of thyroid eye disease activity or duration. LUMVOA is an insulin-like growth factor-1 receptor inhibitor indicated for the treatment of thyroid eye disease regardless of thyroid eye disease activity or duration. ( 1 )

Official sources

Facts only. This site lists what the FDA has approved and what the FDA says each drug is approved for, quoted or closely paraphrased from FDA and openFDA records. It gives no medical advice, no dosing, and no comparisons, and it says nothing about whether a drug is right for anyone. Talk to a licensed clinician about any medication. Records can lag or contain errors; the FDA's own pages are authoritative.